JP2011526620A - プロテアソームモジュレーターとしての窒素複素環誘導体 - Google Patents

プロテアソームモジュレーターとしての窒素複素環誘導体 Download PDF

Info

Publication number
JP2011526620A
JP2011526620A JP2011515719A JP2011515719A JP2011526620A JP 2011526620 A JP2011526620 A JP 2011526620A JP 2011515719 A JP2011515719 A JP 2011515719A JP 2011515719 A JP2011515719 A JP 2011515719A JP 2011526620 A JP2011526620 A JP 2011526620A
Authority
JP
Japan
Prior art keywords
group
iso
groups
branched
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011515719A
Other languages
English (en)
Japanese (ja)
Inventor
ブルーノ・ヴィルトレイ
ミシェル・ルブー−ラヴォー
ニコラ・バス
ジョエル・ヴィダル
マチュー・モンテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2011526620A publication Critical patent/JP2011526620A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
JP2011515719A 2008-07-04 2009-07-03 プロテアソームモジュレーターとしての窒素複素環誘導体 Pending JP2011526620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305377.7 2008-07-04
EP08305377 2008-07-04
PCT/IB2009/052918 WO2010001365A1 (fr) 2008-07-04 2009-07-03 Dérivés hétérocycliques de l'azote sous la forme de modulateurs du protéasome

Publications (1)

Publication Number Publication Date
JP2011526620A true JP2011526620A (ja) 2011-10-13

Family

ID=40030244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515719A Pending JP2011526620A (ja) 2008-07-04 2009-07-03 プロテアソームモジュレーターとしての窒素複素環誘導体

Country Status (4)

Country Link
EP (1) EP2307012A1 (fr)
JP (1) JP2011526620A (fr)
CA (1) CA2728769A1 (fr)
WO (1) WO2010001365A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US9394287B2 (en) * 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
WO2012129564A2 (fr) * 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition de chymotrypsine-like du protéasome à l'aide d'analogues de pi-1833
EP2861588A4 (fr) * 2012-06-15 2016-04-20 Univ California Nouveaux agents thérapeutiques pour le cancer du cerveau
CN103450180B (zh) * 2013-09-24 2015-06-17 湖南大学 2-[4-(苯并噁唑-2-氧基)苯氧基]酰胺的医药用途
CN103497183B (zh) * 2013-09-24 2015-05-13 湖南大学 N-噻唑甲基/甲氧基-2-苯氧基酰胺的医药用途
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
BR112017018198A2 (pt) 2015-02-27 2018-04-10 Curtana Pharmaceuticals Inc inibição da atividade de olig2
WO2017058594A1 (fr) 2015-10-01 2017-04-06 Senomyx, Inc. Composés utiles en tant que modulateurs de trpm8
CN107474043A (zh) * 2017-09-13 2017-12-15 厦门稀土材料研究所 烟酸衍生物及其制备方法与用途
KR101896398B1 (ko) * 2017-11-14 2018-09-07 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
CN112010804A (zh) * 2019-05-31 2020-12-01 中国医学科学院药物研究所 三芳基类化合物及其制法和药物用途
EP4085056A1 (fr) 2020-01-03 2022-11-09 Berg LLC Amides polycycliques utilisés en tant que modulateurs d'ube2k pour le traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068814A1 (fr) * 2005-12-12 2007-06-21 Sanofi-Aventis Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047529A1 (fr) * 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Inhibiteurs de transduction de signaux heterocycliques et compositions les contenant
GB0209891D0 (en) * 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
US7319108B2 (en) * 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2006117669A1 (fr) * 2005-05-03 2006-11-09 Pfizer Inc. Composes d'amide resorcinol
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068814A1 (fr) * 2005-12-12 2007-06-21 Sanofi-Aventis Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013054143; Ｍｏｌｅｃｕｌａｒ　Ｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．７２，　Ｎｏ．３, 2007, ｐｐ．５７２-５８１ *

Also Published As

Publication number Publication date
WO2010001365A1 (fr) 2010-01-07
EP2307012A1 (fr) 2011-04-13
CA2728769A1 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
JP2011526620A (ja) プロテアソームモジュレーターとしての窒素複素環誘導体
US10882835B2 (en) KDM1A inhibitors for the treatment of disease
KR102626978B1 (ko) 질환 치료를 위한 kdm1a 저해제
BR112013002164B1 (pt) Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
CA3061611A1 (fr) Modulateurs de l'interaction sestrine-gator2 et utilisations de ces derniers
JPWO2002076935A1 (ja) 新規α−リポ酸誘導体およびその用途
EP3515449B1 (fr) Dérivés de quinoline en tant qi'inhibiteurs de la protéine chromobox (cbx) pour le traitement du cancer
JP2019530678A (ja) Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤
JPH0541626B2 (fr)
FR3066761A1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
US20110257176A1 (en) Nitrogen heterocycle derivatives as proteasome modulators
EP3464236A1 (fr) Composés et méthodes de régénération hématopoïétique
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
US20190330142A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
WO2010001366A1 (fr) Dérivés de pipérazine en tant que modulateurs du protéasome
JP2020502283A (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤としてのスルホニルアミディーン及びその製造方法と用途
WO2020193431A1 (fr) Nouveaux inhibiteurs de l'histone désacétylase 10
WO2012021982A1 (fr) Agents antifongiques et leurs utilisations
RU2813145C2 (ru) Ингибиторы лизинспецифической гистондеметилазы 1A (KDM1A) для терапии заболеваний
JP2005509673A (ja) 新規な医薬化合物
WO1997046515A1 (fr) Benzenes substitues ne presentant pas d'effets inhibiteurs
WO2023209109A1 (fr) Composés utilisés comme inhibiteurs de l'inflammasome nlrp3 et leur utilisation en tant que médicaments
EP4161651A1 (fr) Inhibiteurs de hck dérivés de quinazoline destinés à être utilisés dans le traitement de maladies à mutation myd88
JP2006008533A (ja) テトラミン誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140421